Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2002

View Archived Issues

New studies on triple therapy for H. pylori eradication reported at WCOG 2002

Merger of Alkermes and Reliant approved by boards of directors

VEGF antagonist attenuates estrogen-mediated increase in uterine mass, endometrial area

17alpha-Methyltestosterone inhibits testosterone-induced breast cancer cell growth

Plant flavonoid displays potent and selective antipoliovirus activity

LM-1685 identified as potent, selective COX-2 inhibitor

Pharmacokinetic and preliminary toxicological data presented for NSC-707545

Chemokine receptor modulators designed at Merck

New class of TAFI inhibitors described by Pfizer particularly for promoting fibrinolysis

5-HT2C antagonists claimed for Rx of anxiety, depression

Boehringer Ingelheim scientists identify new inhibitors of Abeta production

Modulators of histamine H3 receptors patented by Gliatech research team

Mutilin esters and their use in the treatment of infections

Mechanistically different drugs to treat neuropathic pain discussed at the APS meeting

BioXell launched as new biotech company

Avicena receives orphan drug status for creatine in ALS

European Commission provides financial support for diabetes project

TA-HPV gives promising phase II results in HPV-positive AGIN

NPS highlights key developments

Xcellerated T Cells evaluated in hormone-refractory prostate cancer

Nycomed signs deal to become exclusive distributor of Angiomax in 35 countries

Alizyme gets green light for phase Ib trial of ATL-104

MAA submitted for Provigil seeking label expansion in U.K.

Vivitrex enters phase III trial in alcohol-dependent patients, study in opiate users

CpG-7909 in combination with Rituxan evaluated in non-Hodgkin's lymphoma

Shire files for European approval of Xagrid

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...